Mixed data results for two Monte Rosa molecular glue degraders [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
Based in Boston, US, the company has unveiled new data from two trials of its pipeline of molecular glue degraders, including updates from a Phase I single-ascending dose / multiple-ascending dose (SAD/MAD) study of MRT-6160 (NCT06597799) in healthy volunteers. Investigators sought to understand the safety and tolerability of MRT-6160, along with its ability to degrade a nucleotide exchange factor, VAV1. VAV1 plays a crucial role in several immune processes, as well as T-cell and B cell production. Results saw a sustained, dose-dependent VAV1 degradation of more than 90%. At the same time, the oral therapy inhibited the secretion of inflammatory cytokines, such as IL-2, by up to 99%. That first-in-human study recruited 79 patients at sites across the US split into five dose cohorts. Meanwhile, Monte Rosa's Phase I/II trial examining MRT-235 (NCT05546268) has seen its molecular glue degrader targeting GSPT1 fail to produce the expected biomarker positivity rates intended to su
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor MutationsGlobeNewswire
- Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study ResultsGlobeNewswire
- Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]Yahoo! Finance
GLUE
Sec Filings
- 12/16/25 - Form 8-K
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- GLUE's page on the SEC website